Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock Has Average Target Price of $11.50 According to Analysts

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have received an average recommendation of “Moderate Buy” from the seven brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $11.50.

KPTI has been the subject of several research analyst reports. Robert W. Baird cut shares of Karyopharm Therapeutics from an “outperform” rating to a “neutral” rating and set a $3.00 target price for the company. in a research note on Friday, July 31st. Wall Street Zen downgraded shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Piper Sandler dropped their price objective on shares of Karyopharm Therapeutics to $7.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Weiss Ratings lowered shares of Karyopharm Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 24th. Finally, HC Wainwright cut shares of Karyopharm Therapeutics from a “buy” rating to a “negative” rating in a research note on Friday, July 31st.

Karyopharm Therapeutics Stock Performance

Karyopharm Therapeutics stock opened at $0.48 on Tuesday. Karyopharm Therapeutics has a 52 week low of $0.31 and a 52 week high of $10.99. The firm has a market capitalization of $10.93 million, a PE ratio of -0.04 and a beta of 1.04. The business’s 50-day simple moving average is $1.32 and its 200-day simple moving average is $6.17.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($2.32) earnings per share for the quarter, missing the consensus estimate of ($1.37) by ($0.95). The firm had revenue of $33.43 million during the quarter, compared to the consensus estimate of $32.19 million. Research analysts forecast that Karyopharm Therapeutics will post -4.70 earnings per share for the current year.

Hedge Funds Weigh In On Karyopharm Therapeutics

Large investors have recently added to or reduced their stakes in the company. Squarepoint Ops LLC acquired a new stake in shares of Karyopharm Therapeutics during the 2nd quarter worth approximately $623,000. Headlands Technologies LLC bought a new stake in shares of Karyopharm Therapeutics during the second quarter valued at approximately $118,000. Bank of New York Mellon Corp bought a new stake in shares of Karyopharm Therapeutics during the second quarter valued at approximately $559,000. Avidity Partners Management LP raised its stake in shares of Karyopharm Therapeutics by 244.6% in the first quarter. Avidity Partners Management LP now owns 463,741 shares of the company’s stock valued at $2,583,000 after purchasing an additional 329,175 shares in the last quarter. Finally, Royal Bank of Canada raised its stake in shares of Karyopharm Therapeutics by 4.1% in the first quarter. Royal Bank of Canada now owns 60,399 shares of the company’s stock valued at $336,000 after purchasing an additional 2,399 shares in the last quarter. Institutional investors and hedge funds own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. The company’s research centers on selective inhibitors of nuclear export (SINE), a class of compounds designed to interfere with the transport of tumor-suppressing proteins and other molecules in cancer cells.

Karyopharm’s leading product is selinexor, marketed in the United States as XPOVIO and in certain international markets as NEXPOVIO.